As the world observes World Obesity Day, Adalvo highlights its commitment to addressing the global obesity crisis and its close connection to diabetes.
Adalvo’s metabolism and endocrinology portfolio includes 14 INNs, featuring five value-added medicines that provide high-quality, differentiated solutions for healthcare professionals and patients.
The portfolio features a comprehensive Semaglutide range, covering both weight management—generic to Wegovy—and diabetes—generic to Ozempic (0.25mg, 0.5mg, 1mg, and 2mg).
Adalvo was the first to receive EU approval for a GLP-1 medicine and continues to expand its portfolio. Development of generic Wegovy is on track for completion by Q1 2026, while Semaglutide for diabetes is already under registration in multiple countries, with an EU submission planned following data exclusivity expiry.
Adalvo is actively pursuing strategic partnerships to expand access to obesity and diabetes treatments.
Join us in shaping the future of healthcare. For collaboration opportunities, contact our Global Business Development team.
Partner with Us Today